Organophosphate Poisoning

Introduction

Organophosphates (OPs) are esters derived from phosphoric acid. They inhibit acetylcholinesterase, an enzyme that degrades the neurotransmitter acetylcholine. This results in the accumulation of acetylcholine and overstimulation of muscarinic and nicotinic receptors in the central and peripheral nervous systems.

OPs were originally developed as nerve agents for chemical warfare but now have many agricultural uses as insecticides. However, they remain highly toxic to humans and other vertebrates. Common OP pesticides include malathion, parathion, diazinon, fenthion, dichlorvos, chlorpyrifos, and azinphosmethyl.

Acute organophosphate poisoning is a significant clinical problem worldwide, resulting in nearly 300,000 deaths per year. Areas with intensive agriculture such as parts of Asia experience the majority of poisonings through occupational or accidental exposure.

Toxic Doses

The toxicity of an OP depends on its potency as an acetylcholinesterase inhibitor. Very potent OPs may cause symptoms with as little as 1 mg absorbed dose. Moderately toxic OPs require 10-200 mg, while higher doses of less toxic OPs are needed to produce symptoms.

The route of exposure also influences toxicity. Ingestion is the most common route in poisoning cases. Dermal exposure can occur during agricultural work. Inhalation is rare outside industrial accidents.

Factors like the formulation of the OP product can affect absorption. Other individual factors like genetics, age, and existing health conditions may alter susceptibility.

Risk Assessment

A thorough exposure history is required to assess the risk of OP poisoning. Important details include:

• Type of OP compound and its toxicity
• Route, duration, and extent of exposure
• Time elapsed since exposure
• Use of personal protective equipment

The presence of characteristic clinical features like miosis, hypersecretion, fasciculations, respiratory distress, seizures, and loss of consciousness indicate significant poisoning risk. Mild symptoms do not exclude the potential for progression to life-threatening toxicity.

Clinical Examination 

The clinical manifestations reflect the widespread effects of acetylcholine accumulation:

• Muscarinic effects – diarrhea, urination, miosis, bronchospasm, bradycardia, bronchorrhea, emesis, lacrimation, and sweating
• Nicotinic effects – tachycardia, hypertension, fasciculations, paralysis, and potentially respiratory failure
• CNS effects – anxiety, confusion, ataxia, seizures, and coma.

On examination, vitals signs, pupillary size, lung sounds, muscle power, and mental status should be assessed thoroughly. Deteriorating consciousness and respiration indicates severe poisoning.

Investigations

Laboratory testing is not required for diagnosis but can assist monitoring:

• Cholinesterase levels – Red blood cell acetylcholinesterase levels can confirm exposure but do not correlate with severity. Serial levels help monitor response to treatment.
• Arterial blood gas – Assesses oxygenation and ventilation which may be compromised.
• Electrolytes – Imbalances can occur due to hypersecretion.
• Glucose – Hypoglycemia may develop with toxicity.
• ECG – For arrhythmias like bradycardia or QTc prolongation.

Monitoring

All patients with significant poisoning require close monitoring preferably in an intensive care setting. Regular clinical assessment and cholinesterase testing guide the progress.

Monitoring should include:

• Respiratory status with pulse oximetry and ABG analysis
• Cardiovascular parameters like blood pressure and heart rate
• Mental status and neurological symptoms
• Muscle strength and fasciculation activity
• Signs of continuing cholinergic excess like miosis and secretions

Worsening of any parameter indicates the need for additional treatment.

Management and Treatment

The goals of treatment are resuscitation, prevention of absorption, and antidotal therapy.

• Resuscitation – Ensure airway patency, give oxygen, establish IV access, and provide cardiovascular support. Atropine and pralidoxime should be administered early.
• Decontamination – Remove contaminated clothes and wash skin with soap and water to limit absorption. Activated charcoal may be given orally.
• Antidotal therapy
•  -Atropine – Competitively blocks excess acetylcholine at muscarinic receptors. The dose and interval is titrated to drying of secretions. IV atropine boluses of 2-5 mg are given every 5-10 minutes until improvement. Infusions may be required for persistent symptoms. Atropine doses of 100 mg per day may be needed in severe cases.
•  Pralidoxime – Reactivates acetylcholinesterase and reduces toxicity. 1-2 g IV is given over 30 mins and can be repeated after 1 hour if needed. Pralidoxime is continued at 0.5-1 g/hour infusion.
• Supportive care – Provided for complications like respiratory failure, seizures, arrhythmias, hypotension, and hypoglycemia per standard protocols. Intermediate syndrome may require mechanical ventilation.
• Anticonvulsants – Benzodiazepines for seizures. Avoid phenytoin as it may exacerbate toxicity.
• Monitoring – Clinical parameters, cholinesterase levels to guide treatment duration.

The mainstay of therapy is atropine titrated against symptoms along with pralidoxime for reactivation of acetylcholinesterase. Supportive care and monitoring in an intensive care setting is crucial. Most patients recover within 4-6 days with proper treatment.

Conclusion

In summary, organophosphate poisoning is a potentially fatal condition requiring prompt assessment and management. Rapid administration of atropine and pralidoxime can be lifesaving along with supportive care. Clinical monitoring guides the progress of treatment. Prevention through minimization of exposure and use of protective equipment is key to reducing the incidence of this global health problem.